Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection
- PMID: 33059622
- PMCID: PMC7559337
- DOI: 10.1186/s12879-020-05458-w
Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection
Abstract
Background: Infection with the Human Immunodeficiency Virus (HIV) dramatically increases the risk of developing active tuberculosis (TB). Several studies have indicated that co-infection with TB increases the risk of HIV progression and death. Sub-Saharan Africa bears the brunt of these dual epidemics, with about 2.4 million HIV-infected people living with TB. The main objective of our study was to assess whether the pre-HAART CD4+ T-lymphocyte counts and percentages could serve as biomarkers for post-HAART treatment immune-recovery in HIV-positive children with and without TB co-infection.
Methods: The data analyzed in this retrospective study were collected from a cohort of 305 HIV-infected children being treated with HAART. A Lehmann family of ROC curves were used to assess the diagnostic performance of pre- HAART treatment CD4+ T-lymphocyte count and percentage as biomarkers for post-HAART immune recovery. The Kaplan-Meier estimator was used to compare differences in post-HAART recovery times between patients with and without TB co-infection.
Results: We found that the diagnostic performance of both pre-HARRT treatment CD4+ T-lymphocyte count and percentage was comparable and achieved accuracies as high as 74%. Furthermore, the predictive capability of pre-HAART CD4+ T-lymphocyte count and percentage were slightly better in TB-negative patients. Our analyses also indicate that TB-negative patients have a shorter recovery time compared to the TB-positive patients.
Conclusions: Pre-HAART CD4+ T-lymphocyte count and percentage are stronger predictors of immune recovery in TB-negative pediatric patients, suggesting that TB co-infection complicates the treatment of HIV in this cohort. These findings suggest that the detection and treatment of TB is essential for the effectiveness of HAART in HIV-infected pediatric patients.
Keywords: CD4+ T-lymphocytes; immune recovery; HAART; HIV; ROC curves; TB.
Conflict of interest statement
Musie Ghebremichael is an editorial board member of BMC Infectious Diseases journal. Other authors do not have a commercial or other association that might pose a conflict of interest, i.e., authors declare that they have no competing interests to disclose.
Figures




Similar articles
-
The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis.BMC Res Notes. 2025 Jan 7;18(1):6. doi: 10.1186/s13104-024-07032-y. BMC Res Notes. 2025. PMID: 39773670 Free PMC article.
-
Enhanced IFN-γ, but not IL-2, response to Mycobacterium tuberculosis antigens in HIV/latent TB co-infected patients on long-term HAART.BMC Immunol. 2019 Oct 11;20(1):35. doi: 10.1186/s12865-019-0317-9. BMC Immunol. 2019. PMID: 31601184 Free PMC article.
-
Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.BMC Infect Dis. 2017 Jul 25;17(1):517. doi: 10.1186/s12879-017-2627-y. BMC Infect Dis. 2017. PMID: 28743248 Free PMC article.
-
Thymic function in HIV-infection.Dan Med J. 2013 Apr;60(4):B4622. Dan Med J. 2013. PMID: 23651726 Review.
-
Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection.Curr Opin HIV AIDS. 2018 Nov;13(6):455-461. doi: 10.1097/COH.0000000000000501. Curr Opin HIV AIDS. 2018. PMID: 30286038 Review.
Cited by
-
Subdividing ART patients and analyzing the medical burden by modeling of CD4 cell count.J Family Med Prim Care. 2023 Feb;12(2):352-359. doi: 10.4103/jfmpc.jfmpc_1765_22. Epub 2023 Feb 28. J Family Med Prim Care. 2023. PMID: 37091020 Free PMC article.
-
The Prognosis for Delayed Immune Recovery in HIV-Infected Children might be Associated with Pre-cART CD4 + T cell Count Irrespective of Co-Infection with Tuberculosis.Res Sq [Preprint]. 2024 Apr 19:rs.3.rs-4243586. doi: 10.21203/rs.3.rs-4243586/v1. Res Sq. 2024. Update in: BMC Res Notes. 2025 Jan 7;18(1):6. doi: 10.1186/s13104-024-07032-y. PMID: 38699317 Free PMC article. Updated. Preprint.
-
The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4+ T cell count irrespective of co-infection with tuberculosis.BMC Res Notes. 2025 Jan 7;18(1):6. doi: 10.1186/s13104-024-07032-y. BMC Res Notes. 2025. PMID: 39773670 Free PMC article.
-
A study of the top-cited studies on drug therapy for HIV.Front Pharmacol. 2022 Aug 31;13:1007491. doi: 10.3389/fphar.2022.1007491. eCollection 2022. Front Pharmacol. 2022. PMID: 36120330 Free PMC article.
References
-
- Joint United Nations Programme on HIV/AIDS. Global AIDS monitoring 2019: indicators for monitoring the 2016 political declaration on ending AIDS. 2018.
-
- Health TNI Of. Clinical and Laboratory Monitoring of Pediatric HIV Infection https://aidsinfo.nih.gov/guidelines/brief-html/2/pediatric-arv/59/clinic.... Accessed 5 June 2020.
-
- Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2019. 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_.... - PubMed
-
- Zachariah R, Reid SD, Chaillet P, Massaquoi M, Schouten EJ, Harries AD. Viewpoint: why do we need a point-of-care CD4 test for low-income countries?: why do we need a point-of-care CD4 test for low-income countries? Tropical Med Int Health. 2011;16:37–41. doi: 10.1111/j.1365-3156.2010.02669.x. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials